Chicago, IL (PRWEB) November 13, 2013
The birth control safety center at DrugNews.net is announcing updated information for women who’ve taken the drugs Yaz or Yasmin. The maker of the drugs recently disclosed the amount spent so far to settle cases alleging they caused blood clot injuries in patients*.
DrugNews is a free resource for those using popular prescription drugs or medical devices. By learning about the latest safety alerts, recalls, studies and legal news, patients can avoid potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
The resource center has added warnings from health experts like the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, such as Yaz and Yasmin, can increase the risk of blood clots.
A large number of patients have filed a Yaz lawsuit alleging side effects, causing cases to be consolidated in a special federal Multi-District Litigation court. (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)). The latest court records show 9,873 Yaz claims still pending as of October 17****.
Now, DrugNews has added information showing the maker of Yaz and Yasmin, Bayer, has spent around $1.575 billion to settle approximately 7,660 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)*. This amounts to over $205,000 per case.
Lawyers are still helping those affected. Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugNews Center or speak with a lawyer about their options.
Due to the complexity of federal MDL cases, patients should seek a lawyer with experience in defective drug litigation. DrugNews only recommends lawyers who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugNews.net.
*Bayer Stockholder’s Newsletter, Explanatory Notes; Legal Risks, 10/31/13; stockholders-newsletter-q3-2013.bayer.com/en/explanatory-notes.aspx
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****JPML 10/17/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf